India's pharma industry is gearing up to launch over 50 generic brands of weight-loss drugs Ozempic and Wegovy, which are set to go off-patent today. The move is expected to democratize access to these medications in a notoriously price-sensitive market, with prices plummeting by at least 50% compared to branded counterparts.
More than 40 Indian drugmakers are preparing to launch their versions of semaglutide, the key active pharmaceutical ingredient (API) in Ozempic and Wegovy. Analysts project that these generics will debut at steep discounts, with monthly costs for the lowest dose expected to range from ₹3,000 to ₹5,000, down from around ₹11,000.
The influx of generics is a boon for affordability, but healthcare analysts are sounding the alarm over the potential for a regulatory "Wild West" due to concerns over poor dosage titration, unmanaged side effects, and forced regulatory tightening by the state.
Long-term success in the market will rely on clinical trust rather than just rock-bottom pricing, with doctors acting as gatekeepers expected to consolidate their prescriptions around a handful of reliable players who can guarantee supply chain integrity and consistent patient outcomes.
